Eton Pharmaceuticals, Inc. (“Eton”) and Aquestive Therapeutics, Inc. (“Aquestive”) announced that they have entered into an exclusive license agreement and a supply agreement covering the United States and… read more.
Nxera Pharma announces that its subsidiary, Nxera Pharma Japan, has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for… read more.
UCB announced that the FDA has approved the first self-administered once-daily, autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine… read more.
Nearly one-third of people with epilepsy who were prescribed certain hormonal contraceptives also received antiseizure medications that may make those contraceptives less effective, according to a University of… read more.
Scholar Rock announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European… read more.
Sarepta Therapeutics, Inc. presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene… read more.
Tiziana Life Sciences, Ltd. announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy… read more.
Intensive efforts to maintain low blood pressure can lower the incidence of dementia, according to a trial in rural China which was delivered by non-physician healthcare providers. Headline… read more.
Alterity Therapeutics has presented additional analyses from its randomised, double-blind, placebo-controlled ATH434-201 Phase 2 trial in multiple system atrophy (MSA) at the 2026 International Congress of Parkinson’s Disease… read more.
Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive license agreement to develop and commercialize JR-141 in the United States, Europe, and Latin America upon regulatory approval…. read more.
Johnson & Johnson announced new findings on IMAAVY (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) across 15 novel abstracts to be presented at the 2026 Myasthenia… read more.
Vanda Pharmaceuticals Inc. announced positive topline results from its pivotal Phase III study of Hetlioz (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD). Vanda intends… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
